Physician

Jonathan R Whisenant, MD

According to 2025 Medicare claims, Jonathan Whisenant, MD (NPI: 1861441974) practices hematology/oncology in the Salt Lake City-Murray, UT market, with the plurality of this provider's patient population coming from Salt Lake, UT. This provider's primary affiliated billing organization is UTAH CANCER SPECIALISTS PC (NPI: 1619925369; TIN: 870519691) and primary practice location at 84107-5701.

Whisenant's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 306 traditional Medicare patients, billed 122,695 HCPCS/CPT codes, and received $2,445,302 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 577 prescription claims across 120 beneficiaries totaling $2,584,875 in drug costs, led by Revlimid (Lenalidomide). DME data shows 51 claims. Open Payments data shows 10 records totaling $3,727. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $746,191 to $2,445,302. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,084,398 to $2,584,875. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $985 to $882.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	265	41,803	$746,191
2016	165	455	$39,378
2017	181	457	$37,462
2018	160	459	$40,006
2019	205	41,689	$615,375
2020	235	53,175	$988,178
2021	253	72,001	$1,453,884
2022	295	95,105	$1,849,416
2023	297	93,410	$1,779,706
2024	306	122,695	$2,445,302

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	116	504	$1,084,398
2016	73	240	$231,059
2017	89	429	$333,792
2018	83	617	$606,175
2019	84	322	$609,221
2020	86	341	$734,537
2021	102	483	$1,857,727
2022	114	557	$2,101,971
2023	108	431	$1,981,599
2024	120	577	$2,584,875

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	59	$11,195
2016	N/R	22	$544
2017	N/R	N/R	N/R
2018	N/R	42	$7,447
2019	N/R	40	$4,770
2020	N/R	96	$32,617
2021	N/R	90	$34,218
2022	N/R	39	$1,472
2023	N/R	84	$23,653
2024	N/R	51	$1,243

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	180	495	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	100	147	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	78	130	$12
80053	Blood test, comprehensive group of blood chemicals	190	649	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	205	708	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	33	924	$552,912
Jakafi	Ruxolitinib Phosphate	20	600	$321,704
Tagrisso	Osimertinib Mesylate	19	570	$319,638
Pomalyst	Pomalidomide	13	364	$275,403
Everolimus	Everolimus	15	424	$61,771

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$754
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	29	$489

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$140	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$3,587	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$7,071	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Jonathan R. Whisenant, MD?

Tedicare shows public-source Medicare data for Jonathan R. Whisenant, MD (NPI 1861441974), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jonathan R. Whisenant, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jonathan R. Whisenant, MD?

Jonathan R. Whisenant, MD is linked to UTAH CANCER SPECIALISTS PC (billing NPI 1619925369) in the available physician profile data.

Does Jonathan R. Whisenant, MD have Open Payments data?

Jonathan R. Whisenant, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.